Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | GLS | O94925 | 5/20 | 0.38 |
| ▸ | SMO | Q99835 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25059133 | 0.84 | TRPV1 (0.43) | RIPK1SLC6A7NPY1RTRPV1GLS | |
| SCHEMBL5199030 | 0.84 | PDE10A (0.46) | RIPK1SLC6A7TRPV1GLSDPP4 | |
| SCHEMBL25065329 | 0.82 | GLS (0.38) | NPY1RGLSDPP4DPP8DPP9 | |
| SCHEMBL14094520 | 0.81 | NPC1 (0.52) | RIPK1SLC6A7NPY1RTRPV1NPC1 | |
| SCHEMBL12142007 | 0.81 | TRPV1 (0.45) | RIPK1SLC6A7NPY1RTRPV1GLS | |
| SCHEMBL25091313 | 0.80 | GLS (0.43) | RIPK1NPY1RTRPV1GLS | |
| SCHEMBL2000100 | 0.78 | HTR3E (0.54) | RIPK1SLC6A7TRPV1GLSDPP4 | |
| SCHEMBL3715603 | 0.78 | RIPK1 (0.48) | RIPK1SLC6A7TRPV1GLSSMO | |
| Ammonia Solution, Strong SCHEMBL4429607 | 0.77 | KDM4E (0.55) | SMO | |
| SCHEMBL12776572 | 0.77 | TRPV1 (0.45) | RIPK1SLC6A7NPY1RTRPV1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | RIPK1 3349/4885SLC6A7 994/4885NPY1R 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.